Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.44 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23015250 | 1.00 | P2RY10 (0.44) | P2RY10GPR174GPR34 | |
| SCHEMBL26236290 | 0.92 | LPAR3 (0.39) | P2RY10GPR174GPR34 | |
| SCHEMBL20111594 | 0.86 | FABP3 (0.43) | — | |
| SCHEMBL23761110 | 0.86 | FABP3 (0.43) | — | |
| SCHEMBL51010 | 0.86 | FABP3 (0.43) | — | |
| SCHEMBL234142 | 0.84 | ENPP2 (0.51) | — | |
| SCHEMBL26236288 | 0.84 | SELP (0.49) | P2RY10GPR174GPR34 | |
| SCHEMBL14346443 | 0.82 | FABP3 (0.59) | — | |
| SCHEMBL21523585 | 0.82 | FABP3 (0.59) | — | |
| SCHEMBL21370526 | 0.82 | FABP3 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4683666-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683667-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4683665-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | ModernaTX, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250281419-A1 | LIPID AMINES | ARES CAPITAL CORPORATION, AS AGENT | 2025-09-11 | — | — | US | claimed |
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-12-05 | — | — | US | claimed |
| US-20240366522-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2024-11-07 | — | — | US | claimed |
| US-20240335393-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS | ARES CAPITAL CORPORATION, AS AGENT | 2024-10-10 | — | — | US | claimed |
| WO-2024197307-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | MODERNATX, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024197309-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | MODERNATX, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| WO-2024197310-A1 | PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS | MODERNATX, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| CN-118510788-A | Liposoamines | 摩登纳特斯有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-4395748-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4395820-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4376814-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS | ModernaTX, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| EP-4376815-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ModernaTX, Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2023031394-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | CureVac SE (DE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023031392-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023009421-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS | MODERNATX, INC. (US) | 2023-02-02 | — | — | WO | claimed |
| WO-2023009422-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MODERNATX, INC. (US) | 2023-02-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335393-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS | RNGTT, RNMT, AUP1 | P2RY10 3786/4885GPR174 4379/4885GPR34 4806/4885 |
| US-20240366522-A1 | PROCESSES FOR PREPARING LIPID NANOPARTICLE COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | MUC1, EPCAM, ABCB4 | P2RY10 3952/4885GPR174 2928/4885GPR34 3461/4885 |
| US-20240398940-A1 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | ABHD16A, FASN, PHAX | P2RY10 4628/4885GPR174 4135/4885GPR34 4259/4885 |
| US-20250281419-A1 | LIPID AMINES | SGMS1, PHOSPHO1, SGMS2 | P2RY10 3645/4885GPR174 1874/4885GPR34 2238/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | P2RY10 4371/4885GPR174 2527/4885GPR34 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.